The results and the meaning of EMPA-REG OUTCOME and LEADER studies for modern diabetology: in search of ideal combination

Медицинский совет

V. V. Salukhov¹ 

[1]Federal State Budgetary Military Educational Institution of Higher Education Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

关键词: type 2 diabetes;    diabetic drugs;    insulin resistance;    cardiovascular risk;    cardioprotection;    cardiovascular outcomes;   

DOI  :  10.21518/2079-701X-2019-4-44-51

来源: DOAJ

【 摘 要 】

Hyperglycemia is one of the main risk factors for the development of microvascular complications in patients with T2D. However, the main reason of their deaths remain diseases such as myocardial infarction, chronic heart failure, stroke. Although all of the current glucose-lowering drugs are very effective for the correction of hyperglycemia, studies of the last decade proofs that some of them can additionally decrease cardiovascular risk on patients with T2D. So, the influence of empagliflozin, pioglitazone, liraglutide, semaglutide and canagliflozin was characterized as statistically significant positive to the frequency of development of macrovascular complications in patients with T2D. However, nowadays a convincing reduction in cardiovascular mortality in patients with T2D, who took empagliflozin and liraglutide was demonstrated only in two clinical studies - EMPA-REG OUTCOME and LEADER.In the following review there are going to be analyzed the significant results of these studies and the peculiarities of the action of these drugs, which, possibly with joint application, have additive effects in reducing cardiovascular risk in patients with T2D.

【 授权许可】

Unknown